1. Etiologies and epidemiology 2. Staging and local/regional considerations 3. Systemic Therapy 4. Differences in immune checkpoint sensitivity by etiology Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by …

1. Stage II Disease 2. Overview of BEP, EP, VIP 3. Advanced, refractory disease 4. Survivorship considerations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to y…

1. Background, work up 2. Staging of seminoma and NSGCT 3. Young Adult/Adolescent Oncology 4. Management of Stage I Disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizatio…

1. Historical Approach (cytoreduction, IFN-a, sunitinib 2. Prognostic risk scores 3. Evidence for modern doublet regimens 4. Later line therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO a…

1. Risk Factors and Presentation 2. Staging and Paraneoplastic syndromes 3. Localized Therapy Options and Considerations 4. Evidence and Limitations for Adjuvant Systemic Therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of g…

1. Immunohistochemistry of urothelial cancer 2. History of systemic therapy in advanced and metastatic disease 3. Pembrolizumab and Enfortumab Vedotin 4. Approach to second line therapy and beyond Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly enc…

1. Etymology, presentation, and work-up of bladder/urothelial cancer 2. Role of perioperative systemic therapy 3. Tri-modality therapy (bladder sparing approach) 4. Considerations for upper tract urothelial cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.c…

1. Clinical presentation and work-up 2. Intestinal and pancreatobiliary subtypes 3. Role of perioperative therapy 4. Considerations for metastatic disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by A…

1. On continuation of ADT and ARAT switch 2. Systemic therapy options after progression 3. Improper mandated crossover 4. PARP inhibitors in prostate cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by…

1. The chemotherapy revolution in prostate cancer 2. Role of ARATs in earlier disease states 3. Triple therapy (chemotherapy, ADT, and ARAT) 4. Considerations for frailer patients with indolent disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highl…

1. Physiology, efficacy and toxicities of androgen deprivation 2. Evidence for adjuvant intervention after definitive surgery or radiation 3. Role of abiraterone in high-risk localized prostate cancer 4. Limited evidence to support definitive salvage approach Citations As always, citations, and sources include education from our respective training…

1. Background and presentation of prostate Cancer 2. Evidence behind PSA screening and hallmarks of a screening test 3. Staging and risk stratification of Localized Disease 4. Management options and the ProtecT Trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodat…

1. Role for definitive chemotherapy and radiation 2. Controversy on induction chemotherapy 3. Considerations for nasopharyngeal cancer 4. Approach to metastatic HNSCC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines pu…

1. Anatomy, diagnostic work-up and staging 2. Field cancerization 3. Indications for adjuvant concurrent chemoradiation 4. Evidence to support weekly cisplatin with concurrent radiation Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage revi…

1. Presentation, and considerations for regional mesothelioma 2. Systemic therapy options for advanced mesothelioma 3. Corticosteroids for pemetrexed, paclitaxel and docetaxel 4. A quick review on considerations for LCNEC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Up…

1. Background on SCLC 2. Approach to treatment by stage 3. Emerging discussion on prophylactic cranial irradiation 4. Brief review of basket and umbrella trials Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines publishe…

1. Refresher on T+N staging for Stage III 2. Evidence for concurrent chemoradiation 3. PACIFIC Trial 4. Encourage cessation regardless of stage of Lung Cancer Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published …

1. Background on adjuvant EGFR therapy 2. Discussion of initial and updated results 3. Hazard Ratios and Context 4. When crossover and access limit generalizability Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines publ…

1. Considerations with surgery, radiation, rate of relapse 2. Adjuvant chemotherapy 3. Adjuvant immune checkpoint inhibition 4. Emerging neoadjuvant trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by A…

1. EGFR inhibitors 2. ALK inhibitors 3. Less common molecular targets 4. Role of KRAS inhibitors and evidence for sotorasib Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizatio…

1. Evidence to support platinum doublets 2. The tale of pemetrexed 3. Immune checkpoint inhibitors alone and in combination 4. Second Line, approach in progression Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines publi…

1. Presentation and Work-up 2. Staging and how to memorize staging algorithms 3. SVC Syndrome, an oncologic emergency 4. Variations by histology and molecular mutations Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines …

1. Patterns of recurrence and approach to stage IV disease 2. Immunotherapy and BRAF/MEK considerations 3. Cross trial comparisons 4. Later line and emerging therapies for advanced melanoma Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage …

1. Background, staging and work-up of regional melanoma 2. Evidence for adjuvant and neoadjuvant immunotherapy 3. Adjuvant BRAF/MEK inhibitor 4. Considerations for stage IIB/IIC disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage revi…

1. History of Immunotherapy 2. Modern immune checkpoint inhibitors (ICIs) 3. Unique considerations with ICIs 4. Immune related adverse events and immortal time bias in observational studies Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage …

1. BRCA 1/2 genes and relation to malignancy 2. Family history taking and identifying patients for genetic testing 3. Risk reduction strategies for breast and ovarian cancer 4. Systemic therapy considerations in BRCA positive breast cancer Citations As always, citations, and sources include education from our respective training programs, the Devit…

1. Clinical considerations 2. Neoadjuvant and adjuvant regimens 3. Immunotherapy in localized and metastatic disease 4. Later line options in metastatic setting *Erratum- HER-2 Breast cancer <2cm would benefit from an adjuvant regimen (such as trastuzumab and weekly paclitaxel) but typically neoadjuvant is given to 2cm or greater tumors or those th…

1. Role of adjuvant HER-2 Agents and during of therapy 2. Chemotherapy backbone considerations 3. Pathologic complete response 4. Neoadjuvant systemic therapy and response modified approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage …

1. Anti-HER2 agent classes 2. Cleopatra Trial 3. Later line options 4. Leptomeningeal carcinomatosis Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO and other organizations local to your practi…

1. HER-2 Testing Algorithm 2. Trastuzumab Deruxtecan in HER-2 Low MBC 3. 2:1 Randomization, Treatment of Provider Choice 4. Sacutuzumab Govetacan for later line TNBC and HR positive MBC Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage revi…

1. Endocrine Resistance: Definition and Mechanism 2. Role of AI with and without CDK4/6 inhibitors 3. Later line management of metastatic disease 4. Informative Censoring and the BOLERO-2 trial Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encour…

1. Recurrence Risk Scores 2. TailorRx, RxPonder, MINDACT Trials Overview 3. Introduction to CDK 4/6 inhibitors 4. PALLAS and MONARCH-E Discussion Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by ASCO, ESMO…

1. Tamoxifen, its development, mechanism and benefits 2. Aromatase inhibitors and their benefit in post-menopausal state 3. Nuances on extended endocrine therapy beyond 5 years 4. SOFT/TEXT, a broad overview of a complex publication Citations As always, citations, and sources include education from our respective training programs, the Devita textb…

1. First, second, and third generation chemotherapy regimens 2. Considerations for anthracyclines 3. Considerations for taxanes 4. Adjuvant bisphosphonates Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com. We highly encourage review of guidelines published by …

1. History of surgery and radiation for breast cancer 2. Indication and goal of adjuvant systemic therapy (incl cell-kill hypothesis) 3. Overview of breast cancer subtypes 4. Strategies and guidelines for surveillance Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptoda…

1. Overview of disease site 2. Management of localized disease 3. Surveillance 4. Metastatic Disease Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cance…

1. RAPIDO Trial 2. PRODIGE-23 Trial 3. OPRA Trial 4. Evidence for non-operative potential in MSI-H tumors with immune checkpoint inhibition Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg.…

1. Anatomy, definitions, and unique considerations vs colon cancer 2. Surgical modalities and patterns of failure 3. Perioperative radiation and chemoradiation 4. Evidence to support adjuvant systemic therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com De…

1. Overview of intrahepatic, perihilar, distal cholangiocarcinoma 2. Overview of gall bladder adenocarcinoma 3. Adjuvant chemoradiation and chemotherapy considerations 4. Per-protocol, intention to treat analysis, historical controls Citations As always, citations, and sources include education from our respective training programs, the Devita text…

1. Overview of nomenclature, etiology and presentation 2. Management of symptoms and prognosis 3. Systemic therapy in the first line 4. Second line and biomarker driven management Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodo…

1. Differential for pancreatic lesion, staging of adenocarcinoma 2. Surgical considerations, post-surgical complications 3. Historical adjuvant evidence 4. An argument for neoadjuvant systemic therapy Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vi…

1. Natural history of disease, presentation, and diagnosis 2. Principles of management 3. Landmark clinical trials 4. Targeted therapy options as of 2022 Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven…

1. Principles of management 2. Key chemotherapy tegimens 3. Immunotherapy/HER-2 Directed Approach 4. Alpha spending, hierarchical statistical design 5. Later line approach and bottom lines to approach Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vi…

1. Anatomy of the Upper GI Tract 2. Diagnosis, Staging Work-up 3. Neoadjuvant Chemoradiation for Esophageal/EGJ 4. Perioperative and Adjuvant Gastric/EGJ 5. Checkmate 577 discussion Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theo…

IDEA Trial Discussion 1. Background/Methods 2. Non-inferiority Trial Design Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. Devita, Hellman, and Rosenberg's Cancer: Principles & Practice …

1. Clinical Presentation, Pathology Evaluation 2. Chemotherapy Regimens in Adjuvant Setting 3. Approach to Stage 3 4. Approach to Stage 2 Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. D…

1. Background on molecular targeted agents 2. VEGF-inhibitors 3. EGFR inhibition 4. Left vs Right sided colon cancer 5. MSI-H/dMMR status Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, and Uptodate.com DeVita, Vincent T., Jr., Theodore S. Lawrence, and Steven A. Rosenberg. D…

Overview of our podcast and goal.저자 Talking About Tumors

1. Clinical presentations of metastatic colon cancer 2. ECOG performance status 3. 5-fluorouracil and capecitabine 4. Doublet Regimens (FOLFOX/FOLFIRI and derivatives) 5. FOLFOXIRI 6. Considerations for elderly/frail patients Citations As always, citations, and sources include education from our respective training programs, the Devita textbook, an…